{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:41:24Z","timestamp":1780443684860,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.jns.2016.03.024","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T12:22:56Z","timestamp":1458649376000},"page":"190-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial"],"prefix":"10.1016","volume":"365","author":[{"given":"Samuel F.","family":"Hunter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Agius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McCague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetu","family":"Agashivala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2016.03.024_bb0005","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1212\/WNL.46.3.628","article-title":"Depression and multiple sclerosis","volume":"46","author":"Sadovnick","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.03.024_bb0010","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1191\/1352458505ms1162oa","article-title":"The Goldman consensus statement on depression in multiple sclerosis","volume":"11","author":"The Goldman Consensus Group","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2016.03.024_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1034\/j.1600-0404.2001.00022.x","article-title":"Depression and quality of life in multiple sclerosis","volume":"104","author":"Fruehwald","year":"2001","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2016.03.024_bb0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/09638280500191753","article-title":"Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study","volume":"28","author":"D'Alisa","year":"2006","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.jns.2016.03.024_bb0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/1477-7525-11-162","article-title":"Preference-based health status in a German outpatient cohort with multiple sclerosis","volume":"11","author":"Reese","year":"2013","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.jns.2016.03.024_bb0030","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.46.2.552","article-title":"Side effect profile of interferon beta-1b in MS: results of an open label trial","volume":"46","author":"Neilley","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.03.024_bb0035","first-page":"487","article-title":"Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a","volume":"4","author":"Mohr","year":"1998","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2016.03.024_bb0040","series-title":"Manual for the Beck Depression Inventory-II","author":"Beck","year":"1996"},{"key":"10.1016\/j.jns.2016.03.024_bb0045","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of Beck Depression Inventories - IA and - II in psychiatric outpatients","volume":"67","author":"Beck","year":"1996","journal-title":"J. Pers. Assess."},{"key":"10.1016\/j.jns.2016.03.024_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1073191107311261","article-title":"The factor structure of the Beck Depression Inventory-II: an evaluation","volume":"15","author":"Vanheule","year":"2008","journal-title":"Assessment"},{"key":"10.1016\/j.jns.2016.03.024_bb0055","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/da.20002","article-title":"Factor structure, concurrent validity, and internal consistency of the Beck Depression Inventory-Second edition in a sample of college students","volume":"19","author":"Storch","year":"2004","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jns.2016.03.024_bb0060","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1177\/1352458511411061","article-title":"Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study","volume":"17","author":"Montalban","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2016.03.024_bb0065","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3111\/13696998.2013.802239","article-title":"Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design","volume":"16","author":"Cascione","year":"2013","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jns.2016.03.024_bb0070","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.msard.2014.06.005","article-title":"Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, evaluate patient OutComes (EPOC) study in relapsing multiple sclerosis","volume":"3","author":"Fox","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2016.03.024_bb0075","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2016.03.024_bb0080","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.03.024_bb0085","series-title":"SAS\/STAT\u00ae 9.3 User's Guide","author":"SAS Institute Inc","year":"2011"},{"key":"10.1016\/j.jns.2016.03.024_bb0090","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2016.03.024_bb0095","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"11 Suppl.","key":"10.1016\/j.jns.2016.03.024_bb0100","first-page":"8","article-title":"Patient- and physician-reported outcomes after therapy switch from glatiramer acetate to fingolimod versus remaining on glatiramer acetate","volume":"19","author":"Cree","year":"2013","journal-title":"Mult. Scler."},{"issue":"11 Suppl","key":"10.1016\/j.jns.2016.03.024_bb0105","first-page":"8","article-title":"Patient- and physician-reported outcomes after therapy switch from interferon beta to fingolimod versus remaining on interferon beta therapy","volume":"19","author":"Edwards","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2016.03.024_bb0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.lungcan.2008.02.009","article-title":"Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC","volume":"62","author":"Jensen","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jns.2016.03.024_bb0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1524-4733.2007.00200.x","article-title":"Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study","volume":"10","author":"Osborne","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.jns.2016.03.024_bb0120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/annonc\/mdj023","article-title":"A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil\/leucovorin regimens in patients with advanced colorectal cancer","volume":"17","author":"Twelves","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jns.2016.03.024_bb0125","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1191\/1352458503ms915oa","article-title":"Multiple sclerosis and depression: influence of interferon beta therapy","volume":"9","author":"Zephir","year":"2003","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2016.03.024_bb0130","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-4679(200004)56:4<545::AID-JCLP7>3.0.CO;2-U","article-title":"Factor structure of the Beck Depression Inventory-Second edition (BDI-II) in a student sample","volume":"56","author":"Whisman","year":"2000","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.jns.2016.03.024_bb0135","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1023\/A:1025573315492","article-title":"Identification of Beck Depression Inventory items related to multiple sclerosis","volume":"20","author":"Mohr","year":"1997","journal-title":"J. Behav. Med."},{"key":"10.1016\/j.jns.2016.03.024_bb0140","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0000000000000013","article-title":"Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"82","author":"Minden","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.03.024_bb0145","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16301563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16301563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T23:25:22Z","timestamp":1617578722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X16301563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":29,"alternative-id":["S0022510X16301563"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2016.03.024","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2016.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}